Fig. 1: CML patients have unique NK cell repertoire. | Leukemia

Fig. 1: CML patients have unique NK cell repertoire.

From: Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation

Fig. 1

a Schematics showing the overview of data sets, analysis, and validation and extensions. Picture created with biorender.com. b Uniform Manifold Approximation and Projection (UMAP) representation of the pooled RNA profiles of 247,946 CD45+ single-cells including peripheral blood samples from patients with CML (diagnosis n = 4, on TKI n = 6, N = 6, off TKI n = 6, N = 10), patients with untreated hematological cancers (CLL n = 13, AML n = 11), patients with untreated solid cancer (RCC n = 3, NSCLC n = 1), and healthy controls (n = 7). Cells are colored based on the cluster-agnostic, reference-based method Celltypist. On the right, all different conditions are subsampled to 5,000 cells. c The number of predicted cell types and the median proportion of cells within each condition. Colors map to UMAP colors in b. d Differentially abundant scRNAseq populations (Padj < 0.05, Benjamini-Hochberg-corrected two-sided Mann-Whitney test) between patients with CML from different disease phases (n = 10) and healthy controls (n = 7). The horizontal line denotes Padj = 0.05 and the vertical lines log2 fold-change of 1 and −1. e ScRNAseq population abundances in patients with CML (diagnosis n = 4, on TKI n = 6, N = 6, off TKI n = 6, N = 10) and healthy controls (n = 7). P-values were calculated with a two-sided Mann-Whitney test. f ScRNAseq NK population abundances in patients with CML (diagnosis n = 4, on TKI n = 6, N = 6, off TKI n = 6, N = 10), healthy controls (n = 7), patients with untreated hematological cancers (CLL n = 13, AML n = 11), and patients with untreated solid cancer (RCC n = 3, NSCLC n = 1). P values were calculated with a Kruskal-Wallis test. CML=chronic myeloid leukemia, CLL=chronic lymphocytic leukemia, AML= acute myeloid leukemia, RCC=renal cell carcinoma, NSCLC=non-small cell lung carcinoma, TKI=tyrosine kinase inhibitor. n refers to the number of patients and N to the number of samples where it differs from n. *=P < 0.05, **=P < 0.01, ***=P < 0.001, ****=P < 0.0001.

Back to article page